Ophthalmology Times Europe Newsletter

To view this email as a web page, click here.

OTE ISSUE ALERT—October 2019

Volume 15, Issue No. 8

Check out the latest edition!

Why remove an IOL? Survey brings key trends into focus

Accurate IOL measurements, proper patient selection, and solid surgical technique can help to reduce the number of IOL explantations.

Learn more

Facing challenge of corneal infection management in operated eyes

Corneal infections involving surgical interfaces and incisions represent special situations that mandate special considerations for successful management.

Find out

Before brolucizumab’s approval: 96-week visual, expanded anatomical outcomes

Analyses of data collected in phase III clinical trials investigating brolucizumab for the treatment of nAMD provide further evidence that better disease control measured by less fluctuation of OCT-measured fluid is associated with better vision outcomes.

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.